

REMARKS/ARGUMENTS

The claims have been divided into Groups as follows:

- Group 1: Claim(s) 1-14, 33 in part, drawn to a protein/peptide/kit.
- Group 2: Claim(s) 15, drawn to an antibody.
- Group 3: Claim(s) 16-24, 33 in part, drawn to a nucleic acid, primer, vector, cell, mammal, kit.
- Group 4: Claim(s) 25-27, 31-32, drawn to a method of using a chimeric protein.
- Group 5: Claim(s) 28-30, drawn to a method of using cells.

In addition, an election of species, dependent upon Group selection is required as indicated:

If Group 1 is elected: Species 1:

Chimeric protein/peptide: applicant should identify a species of chimeric protein or peptide (claim 14). Applicant should identify the species by amino acid sequence or, for example, by identifying the specific alpha subunit (see claim 6), Beta subunit (see claim 7), and any mutations or labels.

If Group 2 is elected: Species 2:

Antibody: to identify a species of antibody, applicant should identify the species of peptide that the antibody is directed to.

If Group 3 is elected: Species 3:

Nucleic acid/primer/vector: applicant should identify a species of nucleic acid sequence/primer/vector by sequence (see claims 18,20).

If Group 4 is elected: Species 4:

Chimeric protein/peptide: applicant should identify a species of chimeric protein or peptide. Applicant should identify the species by amino acid sequence or, for example, by

identifying the specific alpha subunit (see claim 6), Beta subunit (see claim 7), and any mutations or labels.

If Group 5 is elected: Species 5:

Nucleic acid/vector: applicant should identify a species of nucleic acid sequence/vector by sequence (see claims 18,20) that is in the cells to express the chimeric protein.


Applicants elect, without traverse, Group I, Claims 1-14 and 33, for examination.

As a single disclosed specie, for examination purposes only, Applicants provisionally elect the chimeric protein consisting of a beta 3 subunit fused at its COOH end, with the I-II loop of an alpha subunit. This specie is described in Example 1, beginning on page 25 in the specification and corresponds to Claims 2, 6 and 7.

Applicants respectfully submit that the above-identified application is now in condition for examination on the merits, and early notice thereof is earnestly solicited.

Respectfully Submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon


Jay E. Rowe Jr., Ph.D.
Registration No. 58,948

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 08/07)